A Study of LY3537031 in Overweight, Obese, and Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

302

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

HealthyObesity

Interventions

DRUG

LY3537031

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (5)

Fortrea Clinical Research Unit, Daytona Beach

Clinical Pharmacology of Miami, Miami

QPS, Springfield

Fortrea Clinical Research Unit, Dallas

Collaborative Neuroscience Research, LLC, Los Alamitos

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06606106 - A Study of LY3537031 in Overweight, Obese, and Healthy Participants | Biotech Hunter | Biotech Hunter